Articles Healthcare | Healthcare Insights

top of page

HEALTHCARE INSIGHTS

Healthcare Insights

Healthcare Insights

HEALTHCARE INSIGHTS

The 47th President's first months in office are reshaping the landscape of American medicine. A flurry of executive actions has significantly transformed the nation's health and research agenda, bringing profound implications to patients and businesses alike.

The 47th President's first months in office are reshaping the landscape of American medicine. A flurry of executive actions has significantly transformed the nation's health and research agenda, bringing profound implications to patients and businesses alike.

The First 100 Days: Healthcare Under Trump

7 days ago10 min read

FDA Bans Pharma Employees from Serving on Advisory Committees

FDA Bans Pharma Employees from Serving on Advisory Committees

FDA Bans Pharma Employees from Serving on Advisory Committees

Apr 284 min read

Would a $5K ‘Baby Bonus’ Fix America’s Birth Rate—or Just Fuel the Fertility Industry?

Would a $5K ‘Baby Bonus’ Fix America’s Birth Rate—or Just Fuel the Fertility Industry?

Would a $5K ‘Baby Bonus’ Fix America’s Birth Rate—or Just Fuel the Fertility Industry?

Apr 244 min read

AI is Transforming Biotech Drug Discovery. Here's How:

AI is Transforming Biotech Drug Discovery. Here's How:

AI is Transforming Biotech Drug Discovery. Here's How:

Apr 224 min read

Lilly Surges $100 Billion in Value - Orforglipron Has Markets Buzzing

Lilly Surges $100 Billion in Value - Orforglipron Has Markets Buzzing

Lilly Surges $100 Billion in Value - Orforglipron Has Markets Buzzing

Apr 175 min read

GLP-1 Drugs are Rewriting the Rules of Health, Wealth, & Who Gets Treated

GLP-1 Drugs are Rewriting the Rules of Health, Wealth, & Who Gets Treated

GLP-1 Drugs are Rewriting the Rules of Health, Wealth, & Who Gets Treated

Apr 165 min read

U.S. Tariffs on Chinese Pharmaceuticals to Reshape Global Drug Supply

U.S. Tariffs on Chinese Pharmaceuticals to Reshape Global Drug Supply

U.S. Tariffs on Chinese Pharmaceuticals to Reshape Global Drug Supply

Apr 154 min read

CRISPR 2.0: Base and Prime Editing for Genetic Diseases

CRISPR 2.0: Base and Prime Editing for Genetic Diseases

CRISPR 2.0: Base and Prime Editing for Genetic Diseases

Apr 125 min read

23andMe Bankrupt, Leaving Users' Genetic Data Vulnerable

23andMe Bankrupt, Leaving Users' Genetic Data Vulnerable

23andMe Bankrupt, Leaving Users' Genetic Data Vulnerable

Apr 34 min read

NIH, FDA in Chaos as RFK Makes America "Healthy Again"

NIH, FDA in Chaos as RFK Makes America "Healthy Again"

NIH, FDA in Chaos as RFK Makes America "Healthy Again"

Apr 15 min read

FDA’s Peter Marks Steps Down, Warns of ‘Lies’ & 'Misinformation'

FDA’s Peter Marks Steps Down, Warns of ‘Lies’ & 'Misinformation'

FDA’s Peter Marks Steps Down, Warns of ‘Lies’ & 'Misinformation'

Mar 294 min read

AstraZeneca’s Esobiotec Acquisition: A Move on Cell Therapy

AstraZeneca’s Esobiotec Acquisition: A Move on Cell Therapy

AstraZeneca’s Esobiotec Acquisition: A Move on Cell Therapy

Mar 284 min read

10 Drugs Losing Exclusivity This Year

Mar 258 min read

What You're Missing Without CGMs: Diabetes Care

What You're Missing Without CGMs: Diabetes Care

What You're Missing Without CGMs: Diabetes Care

Mar 244 min read

mRNA beyond vaccines for cancer therapy

mRNA beyond vaccines for cancer therapy

mRNA Tech Beyond Vaccines: Unlocking What's Next in Medicine

Mar 215 min read

Merck Faces Fierce Patent Dispute Over Injectable Keytruda

Merck Faces Fierce Patent Dispute Over Injectable Keytruda

Merck Faces Fierce Patent Dispute Over Injectable Keytruda

Mar 133 min read

Three Months In - Biopharma & Regulation in 2025

Three Months In - Biopharma & Regulation in 2025

Three Months In - Biopharma & Regulation in 2025

Mar 105 min read

Unravelling the Consequences: NIH Budget Cuts Are Affecting Research

Unravelling the Consequences: NIH Budget Cuts Are Affecting Research

Unravelling the Consequences: NIH Budget Cuts Are Affecting Research

Mar 54 min read

Biotech Eikon Therapeutics Raises $350 Million

Biotech Eikon Therapeutics Raises $350 Million

Biotech Eikon Therapeutics Raises $350 Million

Feb 283 min read

Eli Lilly Acquires Organovo’s FXR Agonist for Up to $50 Million, Sparking Stock Surge

Eli Lilly Acquires Organovo’s FXR Agonist for Up to $50 Million, Sparking Stock Surge

Eli Lilly Acquires Organovo’s FXR Agonist for Up to $50 Million, Sparking Stock Surge

Feb 263 min read

Innovation Under Siege: NIH to Cut Billions in Research Funding

Innovation Under Siege: NIH to Cut Billions in Research Funding

Innovation Under Siege: NIH to Cut Billions in Research Funding

Feb 93 min read

2025’s Most Anticipated Drug Launches

2025’s Most Anticipated Drug Launches

2025’s Most Anticipated Drug Launches

Jan 193 min read

GLP-1s May Treat More Than Just Obesity

GLP-1s May Treat More Than Just Obesity

GLP-1s May Treat More Than Just Obesity

Nov 15, 20243 min read

Why Drug Repurposing Can Unlock the Untapped Potential of Existing Medicines

Why Drug Repurposing Can Unlock the Untapped Potential of Existing Medicines

Why Drug Repurposing Can Unlock the Untapped Potential of Existing Medicines

Oct 14, 20244 min read

Funding the Future of Biotech: Venture Capital in 2024

Funding the Future of Biotech: Venture Capital in 2024

Funding the Future of Biotech: Venture Capital in 2024

Sep 10, 20243 min read

Gene Silencing: A New Era of Weight Loss Treatment

Gene Silencing: A New Era of Weight Loss Treatment

Gene Silencing: A New Era of Weight Loss Treatment

Aug 21, 20243 min read

Biotech Clusters: Why Proximity Fuels Breakthroughs

Biotech Clusters: Why Proximity Fuels Breakthroughs

Biotech Clusters: Why Proximity Fuels Breakthroughs

Aug 18, 20244 min read

Big Pharma's Billion-Dollar Bet

Big Pharma's Billion-Dollar Bet

Big Pharma's Billion-Dollar Bet

Aug 14, 20244 min read

What Eli Lilly’s Kisunla Approval Means for Alzheimer’s Patients

What Eli Lilly’s Kisunla Approval Means for Alzheimer’s Patients

What Eli Lilly’s Kisunla Approval Means for Alzheimer’s Patients

Aug 7, 20244 min read

The Supreme Court’s Deference Decision Impacts The FDA & Biotech

The Supreme Court’s Deference Decision Impacts The FDA & Biotech

The Supreme Court’s Deference Decision Impacts The FDA & Biotech

Jul 23, 20243 min read

Why the AntiObesity Market is Expected to Reach $100 Billion by 2030

Jul 12, 20243 min read

Dr. Drew Weissman, Lessons in mRNA Science

Dr. Drew Weissman, Lessons in mRNA Science

Dr. Drew Weissman, Lessons in mRNA Science

Jul 12, 20247 min read

Dr. Katalin Kariko, Insights Into mRNA

Dr. Katalin Kariko, Insights Into mRNA

Dr. Katalin Kariko, Insights Into mRNA

Jul 12, 20245 min read

Price of Progress

Jul 11, 20242 min read

Phage Therapy to Mitigate Antibiotic Resistance

Jul 11, 20243 min read

Personalized Medicine

Jul 11, 20242 min read

Bioprinting Can Revolutionize Medicine

Jul 11, 20244 min read

The Importance of Diversity in Clinical Trials

Jul 11, 20243 min read

Innovations in Drug Delivery

Jul 11, 20243 min read

AI is Accelerating Drug Discovery

Jul 11, 20243 min read

Balancing Progress with Patient Privacy

Jul 11, 20243 min read

Personalizing Medicine is Complex. Here’s Why

Jul 11, 20245 min read

Gene Editing

Jul 11, 20242 min read

CRISPR is Poised to Revolutionize Drug Discovery

Jul 11, 20243 min read

Dr. William G. Kaelin, Lessons from Tumor Metabolism

Dr. William G. Kaelin, Lessons from Tumor Metabolism

Dr. William G. Kaelin, Lessons from Tumor Metabolism

Apr 17, 20245 min read

2024’s Most Anticipated Drug Launches

Apr 15, 20243 min read

Here's Why Pharma is Prioritizing Acquisitions Over R&D

Mar 15, 20244 min read

bottom of page